Epidemiology of Triple Negative Breast Cancer among Cancer Breast Patients and Their Relation to Molecular and Histological Subtypes of Cancer Breast in A Tertiary Care Centre
DOI:
https://doi.org/10.52783/jns.v14.2339Keywords:
Triple-negative breast cancer (TNBC), breast carcinoma, incidence, histopathologyAbstract
Background: A unique subtype of breast cancer called triple-negative breast cancer (TNBC) is distinguished by the lack of expression of the HER2 (human epidermal growth factor receptor 2), PR (progesterone receptor), along with ER (estrogen receptor). In comparison with other subtypes of breast cancer, TNBC has been linked to a worse prognosis and an aggressive clinical course. The goal of this retrospective research is to assess the incidence of TNBC among breast carcinoma patients at a tertiary care hospital, in Chennai. This research also highlights histopathological characteristics and molecular subtypes observed within the sample population.
Methodology: This retrospective analysis was conducted among carcinoma breast patients who presented to the Department of General Surgery, Chettinad Hospital and Research Institute, in the Chennai between January 2021 and January 2024, underwent histopathological testing either by TRUCUT Biopsy or surgical resection. In this study, 58 patients with breast cancer were identified of which 2 were excluded because of lack of PR, ER, HER2/neu status. Statistical analysis was conducted utilizing IBM SPSS version 22.
Results: Overall, 56 cases had been included in our research, Of the 56 patients, 19 (33.92%) were triple negative breast carcinoma. The most common histologic variant was noted to be infiltrating ductal carcinoma (IDC) of no specific type comprising a 64.28% (n=32) of all breast cancers, followed by ductal carcinoma in situ (DCIS) and papillary carcinoma each comprising 12.5% (n=7). Other variants noted included infiltrating ductal carcinoma with medullary changes (8.9%), mucinous adenocarcinoma (3%), a case of apocrine carcinoma (1.7%), and a case of tubular carcinoma (1.7%).
Conclusion: This analysis reveals a higher than average number (33.92%) of TBNC patients in a tertiary hospital, which is in line with the studies done globally. This research demonstrated the need to develop tools to accurately and quickly ascertain the molecular subtypes of breast cancer to guide effective management. Further investigation is necessary to clarify biological and epidemiological factors contributing to the high prevalence of TNBC in this setting.
Downloads
Metrics
References
Makki J. Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. Clin Med Insights Pathol. 2015 Dec 21;8:23-31.
Ensenyat-Mendez M, Llinàs-Arias P, Orozco JIJ, Íñiguez-Muñoz S, Salomon MP, Sesé B, DiNome ML, Marzese DM. Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer. Front Oncol. 2021 Jun 16;11:681476.
Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013 Feb 19;108(3):479-85. Epub 2013 Jan 8.
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007 May 1;109(9):1721-8.
Gonçalves H Jr, Guerra MR, Duarte Cintra JR, Fayer VA, Brum IV, Bustamante Teixeira MT. Survival Study of Triple-Negative and Non-Triple-Negative Breast Cancer in a Brazilian Cohort. Clin Med Insights Oncol. 2018 Jul 27;12:1179554918790563.
Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol. 2009 Apr;20(4):628-35. Epub 2008 Dec 12.
Lehmann BD, Pietenpol JA, Tan AR. Triple-negative breast cancer: molecular subtypes and new targets for therapy. Am Soc Clin Oncol Educ Book. 2015:e31-9.
Kakudji BK, Mwila PK, Burger JR, du Plessis JM, Naidu K. Breast cancer molecular subtypes and receptor status among women at Potchefstroom Hospital: a cross-sectional study. Pan Afr Med J. 2021 Jan 26;38:85.
Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P, Tan PH. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Modern Pathology. 2009 Oct 23;23(1):123-133.
Rao C. Immunohistochemical Profile and Morphology in Triple – Negative Breast Cancers. Journal of Clinical and Diagnostic Research. 2013; cdr/2013/5823.3129
Verma, R., Lal Jakhar, S., Sharma, N., Kumar, H. S., & Beniwal, S. (2021). Epidemiological Profile and Clinicopathological Correlates of Triple Negative Breast Cancer Patients at Regional Cancer Centre. Asian Pacific Journal of Cancer Care, 6(4), 457-460.
Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: review. Pathology. 2009 01;41(1):40-47.
Reis-Filho JS, Tutt ANJ. Triple negative tumours: a critical review. Histopathology. 2007 Dec 13;52(1):108-118.
Dogra A, Doval DC, Sardana M, Chedi SK, Mehta A. Clinicopathological Characteristics of Triple Negative Breast Cancer at a Tertiary Care Hospital in India. Asian Pacific Journal of Cancer Prevention. 2015 01 22;15(24):10577- 10583.
Ishitha G, Manipadam MT, Backianathan S, Chacko RT, Abraham DT, Jacob PM. Clinicopathological Study of Triple Negative Breast Cancers. J Clin Diagn Res. 2016 Sep;10(9):EC05-EC09. Epub 2016 Sep 1.
Ambroise M, Ghosh M, Mallikarjuna VS, Kurian A. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. Asian Pac J Cancer Prev. 2011;12(3):625–29.
Sen S, Gayen R, Das S, Maitra S, Jha A, Mahata M. A clinical and pathological study of triple negative breast carcinoma: experience of a tertiary care centre in eastern India. J Indian Med Assoc. 2012;110(10):686–89, 705.
Verma S, Bal A, Joshi K, Arora S, Singh G. Immunohistochemical characterization of molecular subtypes of invasive breast cancer: a study from North India. Acta Pathol Microbiol Immunol Scand. 2012;120(12):1008–19.
Sandhu GS, Erqou S, Patterson H, Mathew A. Prevalence of Triple-Negative Breast Cancer in India: Systematic Review and Meta-Analysis. J Glob Oncol. 2016;2(6):412-421. Published 2016 Jun 29.
Sarkar S, Akhtar M (2022) Triple Negative Breast Cancer Prevalence in Indian Patients over a Decade: A Systematic Review. Int J Clin Biostat Biom 8:045.
Dhanushkodi M, Sridevi V, Shanta V, et al. Locally Advanced Breast Cancer (LABC): Real-World Outcome of Patients From Cancer Institute, Chennai. JCO Glob Oncol. 2021;7:767-781.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
